Efficacy Testing Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)

Efficacy Testing Market Emerging Trends

Shift toward Advanced In Vitro and Alternative Testing Models Is a Key Trend

• Due to new legislations and people’s rising awareness of the cruelty of animal testing, many companies have abandoned it.
• In vitro testing entails testing products on cells in laboratories, as opposed to animals or human beings.
• In April 2025, the EMA announced plans to simplify biosimilar development and approval with a focus on maintaining strict safety, making these medicines easier to access in Europe.
• 3D cell culture is done to grow artificial tissues in the laboratory that present more properties of the actual human organs.
• The organ-on-a-chip technology involves miniature models of human organs that replicate the functioning of the actual human organs with the use of live cells.
• These new forms of testing are now recognized and embraced by government agencies that regulate food, chemical, and pharmaceutical products, such as the FDA and EMA.
• High-throughput screening employs machines that have the propensity to test thousands of samples within a short time.
• In November 2023, the FDA collaborated with domestic and international government agencies, industry, academia, and regulatory groups, such as Tox21, CAAT, NIST, and ICCVAM.
• The aim was to advance alternative testing methods, including organ-on-chip and in-silico platforms.
• These new methods of testing are cost-saving, quicker, and safer for both people and animals.
• In April 2025, the U.S. Food and Drug Administration said it plans to stop using animal testing for developing monoclonal antibody treatments and other drugs. \
• Instead, it will use new methods that are more relevant to humans, such as AI-based models.
• The FDA has asked for funding to support a new program that focuses on using fewer animals for testing and quickly approving new testing methods.

Rise in Demand for Biologics and Biosimilars Is a Growth Driver

• The growing sale of biopharmaceuticals around the world is a key driver for the market.
• Such medicines are more intricate compared to the ordinary chemical-based therapies and hence, require unique tests to demonstrate efficacy.
• The demand for biologics is rising rapidly due to their ability in treating severe conditions, such as cancer, diabetes, and autoimmune diseases.
• Compared to USD 448.1 billion in 2023, sales of biologics could reach USD 745.1 billion by the year 2030 around the world.
• This presents a huge need to undertake efficiency tests to establish comparison between biosimilars and the native product.
• With the expiration of biologic patents, additional pharmaceutical companies are joining the business of biosimilar development.
• The expanding industry is contributing to the necessity of enhanced efficacy testing methods, as they have to be accurate, reliable, and developed.
• Biosimilars are economical equivalents of high-priced biologics, allowing higher access to advanced treatment.
• Biosimilars have to demonstrate equivalence to their effectiveness and safety as the original biologic; therefore, routine efficacy testing is necessary.

Efficacy Testing Market Segmentation and Category Analysis

Service Type Analysis

The disinfectant analytics category held the larger market share, of 70%, in 2024. This is owing to the growing awareness of personal & environmental hygiene, which has resulted in the increasing use of surface disinfectants.

Further, the advancements in technologies and the surge in the R&D investments by the leading players to deliver the emerging technologies in the market are driving the growth of the category. Moreover, the growing need to ascertain how effective a disinfectant and sanitizing agent is at eliminating microbes is projected to fuel the volume of such tests.

The antimicrobial category will grow at the higher CAGR of approx. 5.5%, during the forecast period is because of the rising use of rapid test techniques. Moreover, global regulatory agencies, such as the FDA, EMA, and CDSCO, are promoting the use of approved rapid detection methods of microbes to reduce the product release time, particularly for time-sensitive pharmaceuticals and biologics. Challenges in conventional testing processes include the increasing demand for personalized medicines and biologic therapies, which have shorter shelf lives, and the necessity in methods that are somewhat faster and more intuitive.

The cosmetics and personal care market shows an increase in demand for clean-label products with low concentrations of preservatives. Producers can accelerate their analyses with lower preservative levels efficacy by using rapid antimicrobial tests without having to wait longer, as in the conventional manufacturing process.

The service types analyzed here are:

• Antimicrobial (Faster-Growing Category)
  • Traditional Test Methods
  • Rapid Test Methods
• Disinfectant (Larger Category)
  • Surface Test Methods
  • Suspension Test Methods

Application Analysis

The biopharmaceuticals category held the largest market share, of 45%, in 2024. This is because pharmaceuticals and biologics regulatory agencies, including the FDA, EMA, and WHO, require comprehensive efficacy and sterility tests on products to ensure product safety, especially for injectable and sterile formulations. The growth of the biopharmaceutical sector due to an increase in the demand for targeted therapies, vaccines, and biosimilars has brought to the market a vast number of products that have to be validated for efficacy. Manufacturers will also spend more on quality control and validation procedures to comply with international requirements, driving the demand routine and advanced efficacy testing solutions.

The cosmetics and personal care products category will grow at the highest CAGR of approx. 4.5%, during the forecast period, because they are increasingly subjected to regulatory compliance, as well as changing consumer demand. Regulatory bodies in the EU and U.S demand strong efficacy evidence that supports product claims, such as anti-aging, moisturizing, and sun protection. Efficacy testing is therefore required to get the product to the market.

Furthermore, the trend of clean-label and low-preservative formulations has multiplied the necessity to research the preservative effectiveness, in order to guarantee the microbiological safety of the product without affecting its composition. Consumers have also become more educated, and they now demand clinically proven results, forcing manufacturers to invest in scientific and standardization testing.

The applications analyzed here are:

• Biopharmaceuticals (Largest Category)
• Cosmetics and Personal Care Products (Fastest-Growing Category)
• Consumer Products
• Medical Devices

Efficacy Testing Market Regional Growth Dynamics

North America held the largest market share, of 52%, in 2024. This is because the major reasons for this include the high adoption rate of advanced techniques and diagnostic tools, highest healthcare and R&D expenditure, and growing outsourcing of testing procedures by pharmaceutical and cosmetics companies in the region. Moreover, the strong presence of the major service providers in the region makes its market lucrative for investors and players. Moreover, the existence of stringent regulations for drug development in the U.S. and the rising count of government initiatives and funding for startups in the domain of life sciences are the other factors that increase the demand for efficacy testing in the U.S.

Further, North America has most of the world’s leading pharma and medical device corporations as well as market players’ headquarters, and other competitors have also concentrated on expanding their geographical presence to advance their market opportunities and capabilities. 

Asia-Pacific is the fastest-growing region, with a CAGR, during the forecast period. The regulatory bodies in the APAC region are tightening their rules to align with international norms. Strict testing procedures are also being imposed by authorities, such as the NMPA in China and CDSCO in India, on pharmaceutical, cosmetic and personal care products. Such tightening in regulation will drive manufacturers to invest in more efficacy validation tests to obtain market clearance.

The APAC cosmetics and personal care market is among the fastest growing in the world, led by India, South Korea, Japan, and China. Consumers here now demand scientific support to the product claims, which propels efficacy testing, particularly for skincare and anti-aging products with or without preservatives. Additionally, the region provides a cost-effective efficacy testing environment, which encourages global companies to outsource efficacy testing services to APAC.

The regions and countries analyzed in this report are:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country Market)
  • Canada
• Europe
  • Germany (Largest Country Market)
  • U.K.
  • France
  • Italy
  • Russia (Fastest-Growing Country Market)
  • Rest of Europe
• Asia-Pacific (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • India (Fastest-Growing Country Market)
  • Japan
  • South Korea
  • Australia
  • Rest of APAC
• Latin America
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa
  • Saudi Arabia (Largest Country Market)
  • South Africa
  • U.A.E. (Fastest-Growing Country Market)
  • Rest of MEA

Efficacy Testing Market Competitive Landscape

The market is fragmented in nature because of the presence of numerous service providers with specialized testing services for various industries. Every industry, pharmaceutical, cosmetic product, personal care, and medical device, requires different efficacy testing protocols. Thus, there is no single provider that can integrate it all together and test them holistically.

The regional variations in regulatory requirements also have AN impact on the market. Different countries have different testing standards and other processes for the acceptance of testing results. Therefore, most companies specialize in certain markets the government regulations of which they know well. That leads to many small and middle-sized providers in various areas. Moreover, the need for customized testing solutions for particular products and applications does not allow the market to be standardized.

Efficacy Testing Market News

• In June 2025, FUNDACIÓN TECNALIA RESEARCH & INNOVATION announced that its biological testing laboratory validated the efficacy of the wood protection products of Mylva sa against boring insects. The testing procedures complied with the EN 118, EN 1390, and EN 46 standards.
• In April 2025, TG Therapeutics Inc. presented the results of the phase 4 clinical trial to conduct the post-marketing observation of BRIUMVI (ublituximab-xiiy) in people with relapsing MS at the 2025 annual meeting of the American Academy of Neurology.
• In March 2025, Almac Group opened a new EUR 65 million commercial manufacturing facility in Craigavon, Northern Ireland. This enhanced its capabilities for commercial oral dose treatment manufacturing with high-specification suites for potent and highly potent drug products.
• In June 2024, Pacific BioLabs earned the ISO 17025 accreditation from A2LA, reinforcing its quality and reliability in efficacy and regulatory testing.
• In April 2024, Charles River Laboratories International Inc. launched the Alternative Methods Advancement Project (AMAP), committing USD 500 million to reduce animal testing. This included the release of Endosafe Trillium, a rapid, animal-free bacterial endotoxin test.